Cure My Disease

Don't miss your cure!

 Log in / Sign up

Diabetes drug could help stop liver damage in hepatitis b patients

NCT ID NCT05147090

Ongoing Disease control Sponsor: The University of Hong Kong Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether empagliflozin, a diabetes drug, can prevent liver scarring (fibrosis) from getting worse in people with chronic hepatitis B. About 106 participants with moderate to severe liver scarring will take either empagliflozin or a placebo daily for three years. The main goal is to see if the drug reduces liver stiffness, a measure of scarring, using advanced imaging.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
empagliflozin
What this could lead to
If it works, this could point toward a new way to slow or stop liver scarring in people with chronic hepatitis B, even if they don't have diabetes.
What could go wrong
This is a small, early-phase trial with only 106 participants. The drug is already approved for diabetes, but its effect on liver fibrosis is unproven. Results may not apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHRONIC HEPATITIS B are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

chronic hepatitis B virus infection cirrhosis of liver Fibrosis fibrotic liver disease hepatitis B virus infection metabolic dysfunction-associated steatotic liver disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CHRONIC HEPATITIS B CIRRHOSIS EMPAGLIFLOZIN FIBROSIS, LIVER NAFLD SGLT2 INHIBITORS

Contacts and locations

Locations

  • The University of Hong Kong/Queen Mary Hospital

    Hong Kong, Hong Kong, China, 852, Hong Kong

More trials for these conditions

Other studies related to the condition(s) this trial covers.